Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953072 | 0.80 | PDE10A (0.46) | PDE10AALDH1A1KDM4EMAPTRAB9A | |
| SCHEMBL13650606 | 0.77 | ALDH1A1 (0.44) | PDE10AALDH1A1KDM4EMAPTRAB9A | |
| SCHEMBL13901457 | 0.77 | PDE10A (0.43) | PDE10AALDH1A1KDM4EMAPTRAB9A | |
| SCHEMBL23994248 | 0.77 | PDE10A (0.43) | PDE10AALDH1A1KDM4EMAPTRAB9A | |
| SCHEMBL3319549 | 0.77 | PDE10A (0.43) | PDE10AALDH1A1KDM4EMAPTRAB9A | |
| SCHEMBL5119212 | 0.73 | PDE10A (0.40) | PDE10AALDH1A1KDM4EMAPTRAB9A | |
| SCHEMBL1370649 | 0.73 | CDK2 (0.40) | PDE10AALDH1A1KDM4EMAPTRAB9A | |
| SCHEMBL15288383 | 0.73 | CDK2 (0.61) | PDE10AALDH1A1KDM4ECDK2 | |
| SCHEMBL24477477 | 0.73 | KDM4E (0.53) | PDE10AALDH1A1KDM4EMAPTRAB9A | |
| SCHEMBL12953633 | 0.72 | PDE10A (0.39) | PDE10AALDH1A1KDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7667036-B2 | MAPKAP-K2 (mitogen-activated protein kinase-activated protein kinase 2) inhibitors; inflammatory, autoimmune disease, destructive bone disorder, cancer and/or tumor growth; angiogenesis, diabetes and neurological disorders | TEIJIN PHARMA LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |